<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151342">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01775189</url>
  </required_header>
  <id_info>
    <org_study_id>B4531009</org_study_id>
    <nct_id>NCT01775189</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Single-Dose, 4-Way Crossover Study to Determine the Relative Abuse Potential of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended Release Capsules) Compared to Oxycodone Immediate Release and Placebo When Administered Intranasally to Non-Dependent, Recreational Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if oxycodone and naltrexone combination
      capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abuse Liability Study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Liking: Peak Effect (Emax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Liking: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again:  Peak Effect (Emax)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Take drug again visual analogue scale (VAS) is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100-point VAS with score ranging from 0 to 100 (score of 0 =</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again:  Mean Effect (Emean)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking:  Peak Effect (Emax)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Drug Liking VAS assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100-point VAS is used to assess response based on a score ranging from 0 to 100 (0 =</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking:  Mean Effect (Emean)</measure>
    <time_frame>12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-8 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Area Under Effect Curve (AUE) From 0-24 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Peak Effect (Emax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-1 Hour for &quot;burning&quot;</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A 6-point scale assessing 5 categories: burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-2 Hours for &quot;burning&quot;</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Rating Scale for Nasal Effects: Peak Effect (Emax) for &quot;burning&quot;</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Rating Scale for Nasal Effects: Time to Maximum (Peak) Effect (TEmax) for &quot;burning&quot;</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of dose (drug powder) insufflated</measure>
    <time_frame>up to 5 min post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight of drug powder remaining (if any) after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-8 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Area Under Effect Curve (AUE) From 0-24 Hours</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Peak Effect (Emax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions.  TEmax = Time to smallest post-dose pupil size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Liking: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleepy: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizzy: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feel Sick:  Time to Maximum (Peak) Effect (TEmax)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Oxycodone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Oxymorphone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Noroxycodone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Naltrexone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of 6-beta-naltrexol</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxycodone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxymorphone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Noroxycodone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of 6-beta-naltrexol</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Oxycodone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Oxymorphone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Noroxycodone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of Naltrexone</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of 6-beta-naltrexol</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxycodone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxymorphone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Noroxycodone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Naltrexone Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-1h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxycodone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxymorphone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Noroxycodone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Naltrexone Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-2h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxycodone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Oxymorphone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Noroxycodone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Naltrexone Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-8h)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Oxycodone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Oxymorphone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Noroxycodone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Naltrexone Concentration (AUClast)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable 6-beta-naltrexol Concentration (AUClast)</measure>
    <time_frame>pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALO-02 weight-matched placebo</intervention_name>
    <description>crushed sugar spheres (powder) x 1 dose</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crushed ALO-02 30 mg/3.6 mg</intervention_name>
    <description>crushed ALO-02 30 mg/3.6 mg capsule x 1 dose</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone weight-matched placebo</intervention_name>
    <description>crushed lactose tablets (powder) x 1 dose</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crushed oxycodone IR 30 mg</intervention_name>
    <description>Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Non-dependent, recreational opioid users.  (Must use opioid for non-therapeutic
             purposes on at least 10 occassions within the last year and at least once in the 8
             weeks before Visit 1 (Screening Visit).

          -  Must have experience with intranasal opioid administration (snorted opioid drugs on
             at least 3 occassions within the last year before Visit 1 (Screening Visit).

        Exclusion Criteria:

          -  Diagnosis of substance and/or alcohol dependence

          -  Subject has participated in, is currently participating in, or seeking treatment for
             substance and/or alcohol related disorder.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531009&amp;StudyName=A%20Study%20to%20Characterize%20the%20Abuse%20Liability%20of%20ALO-02%20in%20Healthy%2C%20Non-Dependent%2C%20Recreational%20Opioid%20Users%20When%20ALO-02%20Capsules%20are%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 11, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relative abuse potential study</keyword>
  <keyword>Chronic pain</keyword>
  <keyword>oxycodone</keyword>
  <keyword>naltrexone</keyword>
  <keyword>opioid-related disorders</keyword>
  <keyword>drug abusers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
